DNA mismatch repair protein gene mutation

4 trials 1 recruiting MedDRA PT
4 Registered trials
1 Recruiting
4 Unique sponsors
2 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Checkpoint inhibitor (PD-L1) 1 substance
Unknown / small molecule 1 substance
Phase II: 1 Phase I: 3

Filter these 4 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 4 trials

Phase II

1 trial
  • AIO-Studien gGmbH Academic
    ATEZOLIZUMAB; MYCOBATERIUM OBUENSE, STRAIN NCTC 13365, HEAT-KILLED
    2024-515224-37-00 1 country 2023 n=80
    Ended

Phase I

3 trials
  • Beigene Ltd. Commercial
    IMP not specified
    2023-503996-38-00 1 country 2025 n=60
    Ended
  • F. Hoffmann-La Roche AG Commercial
    IMP not specified
    2023-503170-20-00 4 countries n=46
    Not authorised
  • Vividion Therapeutics Inc. Commercial
    IMP not specified
    2023-503170-20-01 4 countries 2024 n=80
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Beigene Ltd. Commercial 1 Phase I 0
F. Hoffmann-La Roche AG Commercial 1 Phase I 0
Vividion Therapeutics Inc. Commercial 1 Phase I 1
AIO-Studien gGmbH Academic 1 Phase II 0
New trials by year
2023
1
2024
1
2025
1
← All indication landscapes